Negative $0.78 per share: that is Biohaven's non-GAAP EPS for the reported quarter, arriving $0.17 below analyst consensus. Back the miss out and the implied Street estimate stood at negative $0.61. The deviation works out to roughly 27.9% worse than consensus on a per-share basis.
The controlling figure
The $0.17 shortfall sets the tone. A non-GAAP loss of $0.78 against a consensus of $0.61 is not a rounding-error variance. It is a material undershoot by standard analytical measure. The source discloses only the non-GAAP result; no GAAP EPS figure appears in the available disclosures, so the spread between the two accounting treatments cannot be calculated here.
Non-GAAP reporting excludes items such as stock-based compensation and certain non-cash charges. That treatment is common in biopharma, where non-cash expenses can be large relative to per-share operating losses.
Math reconciliation
| Metric | Value |
|---|---|
| Non-GAAP EPS (reported) | -$0.78 |
| Analyst consensus (implied) | -$0.61 |
| Miss vs. consensus | -$0.17 |
| Miss as % of consensus | ~27.9% |
The consensus figure is back-calculated: the source states both the actual result and the size of the miss, which gives -$0.61 as the embedded Street estimate. No revenue, operating-expense, or cash figures appear in the source, so no further line-item reconciliation is possible.
Positioning read
For a biopharma company still reporting per-share losses, analysts carry assumptions about burn rate and cash runway. A 27.9% EPS undershoot against consensus forces a look at those assumptions. Wider-than-expected losses, all else equal, compress implied runway when measured in quarters. The source provides no cash-on-hand or operating-expense figure, so no specific runway calculation follows from the disclosed data.
The single confirmed fact: Biohaven's non-GAAP EPS of -$0.78 missed the -$0.61 consensus bar by $0.17, marking a quarterly loss materially wider than the Street had modeled.
Related reading
- Gran Tierra Energy Q2 2026: $25 million net income reverses $119 million prior-quarter loss
- 17 S&P 500 companies cleared a triple growth screen, and some trade cheap
- MakeMyTrip posts $51.4 million adjusted operating profit in Q1 FY2027 as hotels and bus offset air softness
- Marshalls posts 13% profit-before-tax gain on flat £380 million first-half revenue